DGAP-News: STRATEC to develop Bio-Rad's next generation blood virus testing analyzer system

STRATEC Biomedical Systems AG / Contract

10.07.2008 

Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------

STRATEC to develop Bio-Rad’s next generation blood virus testing analyzer
system
Birkenfeld, July 10, 2008

STRATEC Biomedical Systems AG, Birkenfeld, Germany, signed an exclusive
agreement with Bio-Rad Laboratories, Inc., Hercules, California, US,
concerning the development and supply of a new family of analyzer systems,
which will automate current and future generations of Bio-Rad's blood virus
diagnostic tests.

Bio-Rad and STRATEC launched a project in January 2008 to develop the new
analyzer system.

Further details concerning the cooperation are subject to a confidentiality
agreement signed between the two parties.


About Bio-Rad

Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb) has remained at the center
of scientific discovery for more than 50 years, manufacturing and
distributing a broad range of products for the life science research and
clinical diagnostics markets. The company is renowned worldwide among
hospitals, universities, major research institutions as well as
biotechnology and pharmaceutical companies for its commitment to quality
and customer service. Founded in 1952, Bio-Rad is headquartered in
Hercules, California, and serves more than 85,000 research and industry
customers worldwide through its global network of operations. The company
employs over 6,300 people globally and had revenues approaching USD 1.5
billion in 2007. For more information, visit http://www.bio-rad.com.


About STRATEC

STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de) designs
and manufactures fully automated analyzer systems for its partners in the
fields of clinical diagnostics and biotechnology. These partners market
such systems, in general together with their own reagents, to laboratories,
blood banks and research institutes around the world. The company develops
its products on the basis of its own patented technologies. Shares in the
company (ISIN: DE0007289001) are traded in the Prime Standard segment of
the Frankfurt Stock Exchange.

The STRATEC Group consists of the publicly listed parent company STRATEC
Biomedical Systems AG and of subsidiaries and second-tier subsidiaries in
Germany, the USA, the UK, Switzerland and Romania.


Further information can be obtained from:

STRATEC Biomedical Systems AG
André Loy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Germany
Phone: +49 7082 7916 190
Fax: +49 7082 7916 999
Email: ir@stratec-biomedical.de
DGAP 10.07.2008 
---------------------------------------------------------------------------
Language:     English
Issuer:       STRATEC Biomedical Systems AG
              Gewerbestraße 37
              75217 Birkenfeld
              Deutschland
Phone:        +49 (0)7082 7916 0
Fax:          +49 (0)7082 7916 999
E-mail:       info@stratec-biomedical.de
Internet:     www.stratec-biomedical.de
ISIN:         DE0007289001
WKN:          728900
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Stuttgart, München, Düsseldorf
End of News                                     DGAP News-Service
---------------------------------------------------------------------------